Organon Launches Publically Accessible Website on Its Clinical Trials
Today Organon announces the launch of a clinical trial website - www.organon-trials.com - that will provide results of the company’s completed trials and a registry of ongoing trials.
June 16, 2005, Oss, The Netherlands - Today Organon announces the launch of a clinical trial website - www.organon-trials.com - that will provide results of the company's completed trials and a registry of ongoing trials. The website will further increase the transparency of the clinical trials Organon sponsors. The site is freely accessible without restriction.
"Organon is committed to provide transparency about the trials we conduct by making this information available in the public domain. We are pleased to be one of the first pharmaceutical companies to introduce such an initiative," commented Dr Henk Jan Out, Head of Global Clinical Development at Organon. With this action, Organon follows the recommendation from the joint pharmaceutical company associations and editors of the major medical journals.
The clinical trial registry contains information on all phase III and beyond trials currently taking place.1 This includes a unique identifying number, purpose of the study, study type and design, eligibility criteria, target number of patients, countries where the study is running and contact information.
The clinical trial results section will summarize the findings of the clinical trials that have been performed with currently available major products of Organon. The number will grow as additional older trials are added. In addition, once trials posted on the registry have been completed and marketing approval gained in one country, the results from all studies - including those preceding the phase III trials - will be posted in the clinical trial results section. Similarly, Organon will also report results of earlier trials when already marketed drugs have been approved in new indications.
Both the registry and results sections provide scientific, non-promotional and comprehensive summaries of clinical trials in a consistent format irrespective of whether the results may be viewed as positive or negative for the medicine concerned. The site will be updated regularly to ensure the information is accurate and up-to-date.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
